Home World China suspends Bristol-Myers' cancer drug sales over findings at U.S. plant

China suspends Bristol-Myers’ cancer drug sales over findings at U.S. plant

The suspension by the China National Medical Products Administration was announced by partner Beigene Ltd and confirmed by Bristol-Myers on Wednesday. Beigene and Bristol-Myers were working to restore supply as soon as possible, said China-based Beigene, which signed an agreement with Bristol-Myers’ Celgene unit in 2017 to market and distribute Abraxane. “This decision only applies to the China market and does not impact our ability to supply Abraxane outside of China,” Bristol-Myers said in an emailed statement.

Read Full Story: Yahoo Finance

- Advertisement -
- Advertisement -
- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Popular